Women with gout: Efficacy and safety of urate‐lowering with febuxostat and allopurinol

Objective To compare the characteristics of female versus male gout patients and assess urate‐lowering efficacy and safety of febuxostat or allopurinol treatment in women with gout. Methods This was a retrospective analysis of 4,101 hyperuricemic (serum urate [sUA] level ≥8.0 mg/dl) gout subjects en...

Full description

Saved in:
Bibliographic Details
Published in:Arthritis care & research (2010) 2012-02, Vol.64 (2), p.256-261
Main Authors: Chohan, Saima, Becker, Michael A., MacDonald, Patricia A., Chefo, Solomon, Jackson, Robert L.
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Aged, 80 and over
Allopurinol - therapeutic use
Cardiovascular Diseases - epidemiology
Comorbidity
Febuxostat
Female
Gout - blood
Gout - drug therapy
Gout - epidemiology
Gout Suppressants - therapeutic use
Humans
Hyperuricemia - blood
Hyperuricemia - drug therapy
Illinois - epidemiology
Male
Metabolic Diseases - epidemiology
Middle Aged
Obesity - epidemiology
Retrospective Studies
Sex Factors
Thiazoles - therapeutic use
Treatment Outcome
Uric Acid - blood
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective To compare the characteristics of female versus male gout patients and assess urate‐lowering efficacy and safety of febuxostat or allopurinol treatment in women with gout. Methods This was a retrospective analysis of 4,101 hyperuricemic (serum urate [sUA] level ≥8.0 mg/dl) gout subjects enrolled in 3 phase III comparative trials and randomized to receive placebo, febuxostat (40 mg, 80 mg, 120 mg, or 240 mg daily), or allopurinol (100 mg, 200 mg, or 300 mg daily, based on renal function). Baseline demographics and characteristics were summarized and compared between female and male subjects. Urate‐lowering efficacy, which was defined as the proportion of subjects with sUA levels
ISSN:2151-464X
2151-4658
DOI:10.1002/acr.20680